Advances in immunotherapy for locally advanced cervical cancer
10.11904/j.issn.1002-3070.2025.02.012
- VernacularTitle:局部晚期宫颈癌免疫治疗进展
- Author:
Mengfei WANG
1
;
Boqun XU
1
Author Information
1. 南京医科大学第二附属医院妇产科(南京 210000)
- Publication Type:Journal Article
- Keywords:
Locally advanced cervical cancer;
Concurrent chemoradiotherapy;
Immune checkpoint inhibitors;
Adverse events
- From:
Practical Oncology Journal
2025;39(2):157-161
- CountryChina
- Language:Chinese
-
Abstract:
Early cervical cancer can be cured through surgery,but about half of patients are already locally advanced at the time of initial diagnosis.Cisplatin-based concurrent chemoradiotherapy is the standard treatment for locally advanced cervical cancer.However,the prognosis of these patients remains poor after completing simultaneous radiotherapy and chemotherapy.The emergence of immunotherapy has dramatically improved the prognosis of patients with advanced and recurrent cervical cancer,and is gradually being combined with conventional treatments such as chemotherapy,radiotherapy and targeted therapy.Recent studies have shown that the combination of pembrolizumab and concurrent radiotherapy significantly improves the progression-free survival rate of patients with lo-cally advanced cervical cancer,without significantly increasing the incidence of toxic side effects;The combination of neoadjuvant chemotherapy with immune checkpoint inhibitors and surgery is expected to become a new treatment option for locally advanced cervi-cal cancer;The use of nabumolizumab immunomaintenance therapy after synchronous radiotherapy and chemotherapy may improve the survival rate and treatment efficacy of patients with locally advanced cervical cancer.This article provides a review of the progress in immunotherapy for locally advanced cervical cancer.
